| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 6LN4W6JJK6 |
| InChI Key | OZZAYJQNMKMUSD-DMISRAGPSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C25H36O5 |
| Molecular Weight | 416.56 |
| AlogP | 4.93 |
| Hydrogen Bond Acceptor | 4.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 80.67 |
| Molecular species | ACID |
| Aromatic Rings | 0.0 |
| Heavy Atoms | 30.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
Ionotropic glutamate receptor
NMDA receptor
|
27600 | - | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Schizophrenia | 2 | D012559 | ClinicalTrials |
| Autistic Disorder | 2 | D001321 | ClinicalTrials |
| Wounds and Injuries | 2 | D014947 | ClinicalTrials |
| Substance Withdrawal Syndrome | 2 | D013375 | ClinicalTrials |
| Low Back Pain | 2 | D017116 | ClinicalTrials |
| Stress Disorders, Post-Traumatic | 2 | D013313 | ClinicalTrials |
| Marijuana Abuse | 2 | D002189 | ClinicalTrials |
| Psychotic Disorders | 2 | D011618 | ClinicalTrials |
| Alcoholism | 0 | D000437 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEBI | 135355 |
| ChEMBL | CHEMBL2105373 |
| DrugCentral | 2256 |
| EPA CompTox | DTXSID40196673 |
| FDA SRS | 6LN4W6JJK6 |
| PubChem | 10070529 |
| SureChEMBL | SCHEMBL667221 |